Multilocus Sequence Typing and Antifungal Susceptibility of Vaginal and Non-vaginal Candida glabrata Isolates From China

Candida glabrata is a common cause of Candida infections. In our present study, we investigated the antifungal susceptibility and molecular epidemiology of vaginal and non-vaginal C. glabrata isolates. Seventy-six vaginal C. glabrata strains isolated from patients with vulvovaginal candidiasis and 57 non-vaginal C. glabrata isolates were collected at two hospitals in Shanghai, China. Antifungal susceptibility was examined using a broth microdilution method. Multilocus sequence typing was used for genotyping. Overall, 28 (21.1%), 28 (21.1%), and 29 (21.8%) C. glabrata isolates were resistant to fluconazole, itraconazole, and voriconazole, respectively. Briefly, 18 (23.7%), 18 (23.7%), and 19 (25%) vaginal strains were resistant to fluconazole, itraconazole, and voriconazole. While the resistance to these antifungals were all 17.5% (10/57) in non-vaginal strains. All isolates retained susceptibility to amphotericin B, and only four non-vaginal isolates were caspofungin resistant. Genotyping identified 17 ST patterns. In non-vaginal samples, the same genotypes appear as in the vaginal samples, except for one genotype (ST-182), while in the vaginal samples more genotypes appear (ST8, ST19, ST45, ST55, ST66, ST80, ST138, and ST17). The most common genotype was ST7 (81 strains), followed by ST10 (14 strains) and ST15 (11 strains). The majority of resistant phenotype strains (25/30, 83.3%) correlated to the predominant genotype (ST7), and the rest belonged to ST3 (2/30, 6.7%), ST10 (1/30, 3.3%), ST19 (1/30, 3.3%), and ST45 (1/30, 3.3%). Our survey revealed cross-resistance in vaginal and non-vaginal C. glabrata isolates. Moreover, there is no genotype associated with the resistance phenotype.

[1]  P. Escribano,et al.  Antifungal Susceptibility Testing Identifies the Abdominal Cavity as a Source of Candida glabrata-Resistant Isolates , 2021, Antimicrobial agents and chemotherapy.

[2]  L. Zeng,et al.  Molecular Epidemiology, Antifungal Susceptibility, and Virulence Evaluation of Candida Isolates Causing Invasive Infection in a Tertiary Care Teaching Hospital , 2021, Frontiers in Cellular and Infection Microbiology.

[3]  Alaaldin M. Alkilany,et al.  Silver nanoparticles, a promising treatment against clinically important fluconazole‐resistant Candida glabrata , 2021, Letters in applied microbiology.

[4]  E. Ay,et al.  Genotyping, drug resistance and virulence factors of Candida species isolated from patients using long‐term inhaled steroids , 2021, International journal of clinical practice.

[5]  L. Than,et al.  Candida glabrata: Pathogenicity and Resistance Mechanisms for Adaptation and Survival , 2021, Journal of fungi.

[6]  T. Wongsuk,et al.  Species Distribution, Antifungal Susceptibility, and Molecular Epidemiology of Candida Species Causing Candidemia in a Tertiary Care Hospital in Bangkok, Thailand , 2021, Journal of fungi.

[7]  S. Kotoulas,et al.  Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible? , 2021, Infection.

[8]  V. F. Gimenes,et al.  Antifungal susceptibility profile of Candida clinical isolates from 22 hospitals of São Paulo State, Brazil , 2021, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[9]  Márcia Eliana da Silva Ferreira,et al.  Genetic diversity assessed using PFGE, MLP and MLST in Candida spp. candidemia isolates obtained from a Brazilian hospital , 2021, Brazilian Journal of Microbiology.

[10]  Yue Zheng,et al.  Strain Distribution and Drug Susceptibility of Invasive Fungal Infection in Clinical Patients With Systemic Internal Diseases , 2021, Frontiers in Bioengineering and Biotechnology.

[11]  Wei Liu,et al.  Prevalence and Antifungal Susceptibility of Pathogenic Yeasts in China: A 10-Year Retrospective Study in a Teaching Hospital , 2020, Frontiers in Microbiology.

[12]  K. Kamei,et al.  Genetic Basis of Azole and Echinocandin Resistance in Clinical Candida glabrata in Japan , 2020, Antimicrobial Agents and Chemotherapy.

[13]  Yin-Huan Ding,et al.  A seven-year surveillance study of the epidemiology, antifungal susceptibility, risk factors and mortality of candidaemia among paediatric and adult inpatients in a tertiary teaching hospital in China , 2020, Antimicrobial Resistance & Infection Control.

[14]  F. Kong,et al.  Distribution and Antifungal Susceptibility of Candida Species Causing Candidemia in China: An Update From the CHIF-NET Study. , 2020, The Journal of infectious diseases.

[15]  A. Mahmoudabadi,et al.  Microsatellite Typing and Antifungal Susceptibility of Candida glabrata Strains Isolated From Patients With Candida Vaginitis , 2019, Front. Microbiol..

[16]  Xiaobo Hu,et al.  Mechanisms of azole resistance in clinical isolates of Candida glabrata from two hospitals in China , 2019, Infection and drug resistance.

[17]  F. Bongomin,et al.  An Update on the Roles of Non-albicans Candida Species in Vulvovaginitis , 2018, Journal of fungi.

[18]  A. Chowdhary,et al.  Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris , 2018, Journal of Intensive Care.

[19]  Mina Kim,et al.  Multilocus Sequence Typing (MLST) Genotypes of Candida glabrata Bloodstream Isolates in Korea: Association With Antifungal Resistance, Mutations in Mismatch Repair Gene (Msh2), and Clinical Outcomes , 2018, Front. Microbiol..

[20]  A. De Las Peñas,et al.  Adhesins in Candida glabrata , 2018, Journal of fungi.

[21]  W. Liao,et al.  Epidemiology of fungal infections in China , 2018, Frontiers of Medicine.

[22]  M. Shams-Ghahfarokhi,et al.  Genotyping of clinical isolates of Candida glabrata from Iran by multilocus sequence typing and determination of population structure and drug resistance profile , 2018, Medical mycology.

[23]  Ziyong Sun,et al.  Molecular Epidemiology and Antifungal Susceptibility of Candida glabrata in China (August 2009 to July 2014): A Multi-Center Study , 2017, Front. Microbiol..

[24]  J. Meis,et al.  In Vitro Antifungal Susceptibility Testing of Candida Isolates with the EUCAST Methodology, a New Method for ECOFF Determination , 2017, Antimicrobial Agents and Chemotherapy.

[25]  N. Wiederhold Echinocandin Resistance in Candida Species: a Review of Recent Developments , 2016, Current Infectious Disease Reports.

[26]  Thi Thanh Nga Tran,et al.  Antifungal susceptibility of invasive Candida bloodstream isolates from the Asia-Pacific region. , 2016, Medical mycology.

[27]  J. Buer,et al.  Echinocandin resistance and population structure of invasive Candida glabrata isolates from two university hospitals in Germany and Austria , 2016, Mycoses.

[28]  S. Ranque,et al.  MALDI-TOF typing highlights geographical and fluconazole resistance clusters in Candida glabrata. , 2015, Medical mycology.

[29]  Ashish Gupta,et al.  Candida glabrata candidemia: An emerging threat in critically ill patients , 2015, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.

[30]  Arunaloke Chakrabarti Candida glabrata candidemia , 2015, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.

[31]  D. Soll,et al.  Multilocus Sequence Typing of Candidaglabrata Reveals Geographically EnrichedClades , 2003, Journal of Clinical Microbiology.